Could technology help contain the next equine flu epidemic?
Humanity has endured infectious disease epidemics for as long as it’s existed. However, as global connectivity grows so does the rate at which they can spread and the number of people they can affect. The origin of epidemics is the random genetic mutation of pathogens so we have no control over their arrival but technology offers very real control over the way they spread.
New modes of drug action tackle intractable diseases
2018 was a busy one for the US Food and Drug Administration. Drug approvals hit a record high, with 59 novel drugs securing the agency’s permission to head to market. This included a number of drugs with modes of action that transcend the two main classes of drugs.
No pain, no gain: R&D challenges for the success of microneedle systems
Microneedle systems pose multidisciplinary R&D challenges—some because of and some despite the much smaller size of the needles involved. But microneedle systems also offer exciting new prospects for drug delivery and multiplex biomarker detection. This information could be used to guide personalised treatment or enable value-based healthcare.
The future of molecular diagnostics: Will isothermal amplification techniques steal PCR’s crown in the close-to-patient era?
PCR is still the go-to method in the molecular diagnostics industry but, with the rise of close-to-patient testing, isothermal amplification methods with their low power and potentially easier detection schemes look increasingly attractive.
Remote monitoring and telemedicine: a match made in digital health heaven?
It’s tempting to think that IoT infrastructure and AI make remote disease monitoring straightforward. But even when this is technically feasible, healthcare system innovation is necessary to make the most of opportunities created by digital health.
Can we imagine a future of personalised medicine based on the analysis of lipids and carbohydrates?
DNA to RNA to protein – from this simple but powerful concept was born first biotechnology and then personalised medicine. But are we missing something? Can we imagine a future of personalised medicine based on the analysis of lipids and carbohydrates?
Design for adherence: a model for predicting and improving medication adherence
Medication adherence is often studied after a drug or delivery device has been developed, but what if we were able to predict levels of adherence for a particular drug delivery device during development?
Beyond pixel number: Where next for endoscopic imaging capabilities?
Relentless progress in imaging sensors driven by the smart phone camera revolution is beginning to transform the optical capabilities of endoscopes. Beyond pixel number, this also raises the prospect of challenger business models that offer altogether new imaging capabilities, or disposable endoscopes.
Driving Cell Therapy Innovation: Applying Key Lessons from the Evolution and Commercialization of Protein-Based Therapies
Bioprocess International Conference in Boston panel.
New dimensions in 3D bioprinting
Late stage failures in drug development are extremely costly for pharmaceutical companies and stifle innovation. Now non-traditional methods such as 3D bioprinting are being brought to bear on this challenge.